Vivalia Remedies Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Vivalia Remedies Private Limited Pharmaceutical Export Portfolio Dataset — 3 Products, $697.8K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Vivalia Remedies Private Limited — Pharmaceutical Exporter Profile (2026) | 3 Products, $697.8K Trade | TransData Nexus

Vivalia Remedies Private Limited

Indian Pharmaceutical Exporter · Advanced Oncology Specialist · $697.8K Total Trade · DGFT Verified

Vivalia Remedies Private Limited is an Indian pharmaceutical exporter with a total trade value of $697.8K across 3 products in 2 therapeutic categories. Based on 15 verified export shipments from Indian Customs (DGFT) records, Vivalia Remedies Private Limited is the #1 Indian exporter in 1 product including Ifosfamide. Top exports include Ifosfamide ($350.0K), Bleomycin ($200.0K), Cyclophosphamide ($147.8K).

Vivalia Remedies Private Limited — Export Portfolio & Destination Treemap

Vivalia Remedies Private Limited pharmaceutical export portfolio — 3 products across 2 therapeutic categories. Source: Indian Customs (DGFT).

Who is Vivalia Remedies Private Limited? — Company Overview & Market Position

Vivalia Remedies Private Limited is an Indian pharmaceutical exporter established on September 2, 2011, in New Delhi, Delhi, India. The company is registered under the Corporate Identification Number (CIN) U74900DL2011PTC224457. It operates as a private limited company, unlisted on stock exchanges, with an authorized and paid-up capital of ₹100,000.

The registered office is located at L 69/A, Third Floor, New Delhi, Delhi, 110017. The company's primary business activity is drug formulation and development, focusing on the export of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections.

Financially, Vivalia Remedies has experienced fluctuations in recent years. In the fiscal year ending March 31, 2024, the company reported a 50.76% decrease in total revenue compared to the previous year. Despite this decline, the net worth increased by 19.73%, indicating a strengthening financial position.

What Does Vivalia Remedies Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Ifosfamide$350.0K

Product Portfolio — Top 3 by Export Value

Vivalia Remedies Private Limited exports 3 pharmaceutical products across 2 therapeutic categories. Market leader (#1 exporter) in 1 products.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Ifosfamide	Advanced Oncology	$350.0K	7	14.3%	1
2	Bleomycin	Advanced Oncology	$200.0K	4	3.6%	5
3	Cyclophosphamide	Oncology	$147.8K	4	0.8%	10

Vivalia Remedies Private Limited exports 3 pharmaceutical products across 2 therapeutic categories with a total export value of $697.8K. The company is the #1 Indian exporter in 1 product: Ifosfamide. The top category is Advanced Oncology (78.8% of portfolio), followed by Oncology (21.2%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Vivalia Remedies Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Specific details regarding Vivalia Remedies Private Limited's manufacturing facilities, including locations, capacities, and specializations, are not publicly disclosed. The company focuses on the export of finished pharmaceutical formulations, suggesting that its manufacturing operations are aligned with this product line. However, without explicit information, a comprehensive assessment of their manufacturing capabilities cannot be provided.

3Key Leadership

Vivalia Remedies Private Limited is led by two directors:

Vaibhav Ahluwalia Kumar: Appointed on September 2, 2011, he serves as a director of the company.

Praveenkumari Ahluwalia: Also appointed on September 2, 2011, she holds the position of director.

The company's leadership structure is relatively simple, with these two individuals at the helm. No additional key executives or management personnel are publicly listed, indicating a streamlined organizational hierarchy.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Vivalia Remedies Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Vivalia Remedies Private Limited's presence in regulated markets such as the United States, European Union, United Kingdom, Australia, and Japan is not explicitly detailed in the available public records. The company's export data indicates a focus on oncology products, including Ifosfamide, Bleomycin, and Cyclophosphamide, which are critical in cancer treatment. However, without specific regulatory filings or approvals, it is challenging to ascertain the company's market access status in these regions.

2Emerging Markets

Vivalia Remedies Private Limited's export data highlights a significant focus on oncology products, particularly Ifosfamide, Bleomycin, and Cyclophosphamide. While the company's export activities suggest a potential presence in emerging markets, specific information regarding its penetration in regions such as Africa, Latin America, and Southeast Asia is not publicly available. The company's emphasis on oncology products may align with the growing demand for cancer treatments in these regions. However, without explicit data, a detailed analysis of their market presence cannot be provided.

3Geographic Strategy

Vivalia Remedies Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific details regarding Vivalia Remedies Private Limited's interactions with the U.S. Food and Drug Administration (FDA), including facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history, are not publicly available. The company's export data does not provide insights into its regulatory standing with the FDA. Without explicit information, a comprehensive assessment of the company's FDA status cannot be conducted.

2WHO & EU GMP

Information regarding Vivalia Remedies Private Limited's compliance with World Health Organization (WHO) prequalification, European Union Good Manufacturing Practice (EU GMP) certificates, or European Directorate for the Quality of Medicines & HealthCare (EDQM) status is not publicly disclosed. The company's export data does not indicate adherence to these international quality standards. Without specific certifications or approvals, it is challenging to evaluate the company's compliance with WHO and EU GMP requirements.

3CDSCO & Indian Regulatory

Vivalia Remedies Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Vivalia Remedies Private Limited operates in the oncology pharmaceutical sector, focusing on products like Ifosfamide, Bleomycin, and Cyclophosphamide. The competitive landscape in this niche is characterized by several established global and regional players. While specific market share data is not available, the company's emphasis on advanced oncology products positions it in a competitive market segment. A detailed head-to-head analysis would require access to proprietary market intelligence and competitor data.

2Key Differentiators

Vivalia Remedies Private Limited's key differentiators include its specialized focus on oncology products, particularly in the advanced oncology category, which constitutes 78.8% of its export value. The company's portfolio concentration on a select number of products may allow for specialized expertise and quality control. However, this focus also exposes the company to risks associated with market fluctuations and regulatory changes affecting these specific products.

3Strategic Position

Vivalia Remedies Private Limited's current strategic direction appears to be centered on the export of oncology products, with a strong emphasis on advanced oncology treatments. The company's concentrated product portfolio suggests a strategy focused on depth rather than breadth. Future outlooks would benefit from diversification into other therapeutic areas or product lines to mitigate risks associated with market concentration and to capitalize on emerging opportunities in the global pharmaceutical market.

Buyer Due Diligence Brief — Evaluating Vivalia Remedies Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Vivalia Remedies Private Limited's track record as a supplier is not extensively documented in the available public records. The company's export data indicates a focus on oncology products, with a total export value of $698,000 USD across 15 shipments. The portfolio concentration on a limited number of products may suggest a specialized and consistent supply capability. However, without detailed information on customer feedback, delivery performance, and quality metrics, a comprehensive assessment of the company's reliability as a supplier cannot be conducted.

2Certifications to Verify

Importers considering Vivalia Remedies Private Limited as a supplier should verify the following certifications to ensure product quality and regulatory compliance:

FDA Approval: Confirm that the company's products are approved by the U.S. Food and Drug Administration. Verification can be done through the FDA's official website or by contacting the company directly.

WHO-GMP Certification: Ensure that the manufacturing facilities comply with World Health Organization Good Manufacturing Practice standards. This can be verified by reviewing the company's certifications or by contacting the World Health Organization.

Frequently Asked Questions — Vivalia Remedies Private Limited

How many pharmaceutical products does Vivalia Remedies Private Limited export from India?

Vivalia Remedies Private Limited exports 3 pharmaceutical products across 2 therapeutic categories. The top exports are Ifosfamide ($350.0K), Bleomycin ($200.0K), Cyclophosphamide ($147.8K). Total export value is $697.8K.

What is Vivalia Remedies Private Limited's total pharmaceutical export value?

Vivalia Remedies Private Limited's total pharmaceutical export value is $697.8K, based on 15 verified shipments recorded in Indian Customs (DGFT) data.

In which products is Vivalia Remedies Private Limited the #1 Indian exporter?

Vivalia Remedies Private Limited is the #1 Indian exporter in 1 products: Ifosfamide (14.3% market share).

What therapeutic categories does Vivalia Remedies Private Limited cover?

Vivalia Remedies Private Limited exports across 2 therapeutic categories. The largest are Advanced Oncology (78.8%, 2 products), Oncology (21.2%, 1 products).

Get Full Vivalia Remedies Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.